All

FDA Approves Genentech’s Alecensa for Early-Stage ALK-Positive NSCLC

Genentech says the approval makes the drug the first ALK inhibitor for patients with ALK-positive, early-stage non-small cell lung cancer who have undergone surgery.

All

FDA Approves Osimertinib plus Chemotherapy for EGFR-mutated NSCLC

The FDA approved osimertinib (Tagrisso) with platinum-based chemotherapy for certain patients with non-small cell lung cancer (NSCLC).

All

Children’s Homes Harboring Invisible Threat of Thirdhand Smoke

A University of Cincinnati researcher discovers that toxic residues from tobacco smoke, known as thirdhand smoke, linger on household surfaces, posing a serious health risk to children.

AstraZeneca’s NSCLC Therapy Imfinzi Misses Primary Endpoint in Ph3 Study

by RT Staff | Nov 27, 2023 | Clinical Trials, Lung Cancer, US Pharmaceuticals | 0

AstraZeneca’s Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.

FDA Approves Bristol Myers’ Non-Small Cell Lung Cancer Drug

by RT Staff | Nov 16, 2023 | FDA Approvals, Lung Cancer | 0

Augtyro was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Lung Cancer Survival Rates ‘Improving for Everyone,’ National Report Reveals

by RT Staff | Nov 14, 2023 | Lung Cancer | 0

The American Lung Association’s 2023 “State of Lung Cancer” report reveals improvement in five-year survival rate across the US, including for people of color.

Early CT Screening Skyrockets Long-term Lung Cancer Survival Rates

by RT Staff | Nov 7, 2023 | Clinical, Diagnostics, Lung Cancer | 0

Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves its cure rate measured over a 20-year period, according to a large-scale study.

New Lung Cancer Screening Guideline Expands Eligibility

by RT Staff | Nov 1, 2023 | Association News, Clinical, General Healthcare, Lung Cancer, Testing, Tobacco | 0

Nearly 5 million US adults who smoke and formerly smoked are now recommended for testing.

Immunotherapy Before and After Surgery Boosts Lung Cancer Outcomes

by RT Staff | Oct 26, 2023 | Clinical Trials, Lung Cancer, US Pharmaceuticals | 0

Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.

Enhertu Approved in the EU for Certain NSCLC Patients

by RT Staff | Oct 24, 2023 | Intl' Pharmaceuticals, Lung Cancer | 0

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the EU as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

Datopotamab Deruxtecan Improved NSCLC Survival

by RT Staff | Oct 24, 2023 | Clinical Trials, Lung Cancer, US Pharmaceuticals | 0

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors, according to Phase 3 trial data.

Positive Data for Tagrisso in Patients with EGFR-mutated NSCLC

by RT Staff | Oct 21, 2023 | Clinical Trials, Intl' Pharmaceuticals, Lung Cancer | 0

A Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) plus chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline.

Tag: lung cancer

All

All

All